Archives
-
Q-VD(OMe)-OPh for Reliable Apoptosis Assays
2026-08-27
Learn how Q-VD(OMe)-OPh (SKU A8165) can help laboratories distinguish caspase-dependent apoptosis from ferroptosis, autophagy, and other causes of reduced viability. This scenario-based guide covers assay design, solvent handling, data interpretation, and practical supplier-selection criteria.
-
Macrophage Depletion as a Causal Test in Liver I/R
2026-08-26
A translational framework for using Clodronate Liposomes to test whether macrophage populations are necessary for paeoniflorin-mediated protection in hepatic ischemia-reperfusion injury, while preserving mechanistic rigor, experimental controls, and realistic expectations for clinical translation.
-
L-NAME Hydrochloride for Reliable Cell Assays
2026-08-25
Learn how L-NAME Hydrochloride (SKU A7088) can help researchers separate nitric oxide biology from assay noise in viability, proliferation, cytotoxicity, and vascular studies. This scenario-based guide covers concentration selection, solvent compatibility, controls, interpretation, and practical product evaluation.
-
PF-573228: FAK Inhibitor Workflow Guide
2026-08-24
PF-573228 provides a tunable way to test how focal adhesion kinase converts matrix mechanics into cell fate, migration, and survival signals. This practical guide connects stiffness-controlled dentinogenesis assays with endothelial and cancer models while emphasizing dose control, phospho-FAK validation, and troubleshooting.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-23
This 2026 FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The formulation restored nuclear p21, altered cell-cycle and DNA-damage markers, suppressed orthotopic tumor growth, and produced strong bladder-localized expression with limited systemic distribution in mice.
-
Macrophage TIPE2 Drives ASC Ferroptosis in Obesity
2026-08-22
This Nature Communications study identifies a macrophage–adipose stem cell circuit that links obesity-associated inflammation to ferroptotic loss of adipose stem cells and visceral fat dysfunction. Its central mechanistic insight is that macrophage TIPE2 preserves exosomal ferritin delivery by restraining the IP3R–Ca2+–Drp1 mitochondrial fission axis, suggesting a cellular route for restoring adipose tissue homeostasis.
-
Mitoxantrone HCl: Practical DNA Damage Workflows
2026-08-21
Mitoxantrone HCl supports more than conventional cytotoxicity studies: it enables controlled investigation of topoisomerase II-mediated DNA damage, apoptosis, immune-cell modulation, and ERα degradation. This bench-focused guide covers formulation, dose-response design, orthogonal readouts, and troubleshooting for cancer and stem-cell models.
-
Tirbanibulin in HPV-Positive HeLa Cells
2026-08-16
This 2024 study shows that tirbanibulin suppresses proliferation of HPV-18-containing HeLa cells while reducing protein expression across Src–MEK-associated, cell-cycle, invasion, and survival pathways. Its integrated immunoblotting approach provides a mechanistic framework for understanding how an approved actinic keratosis treatment may also affect HPV-associated oncogenic signaling, while leaving direct antiviral and clinical efficacy questions unresolved.
-
ATM Inhibition and Fenofibrate in HGSOC
2026-08-15
The reference study identifies a metabolic vulnerability associated with ATM activity in high-grade serous ovarian cancer (HGSOC). It shows that pharmacologic ATM inhibition can synergize with fenofibrate, a PPARα agonist, to induce senescence in HGSOC cells, offering a combination strategy that extends beyond conventional DNA damage-based treatment.
-
AZD0156: Reliable ATM Inhibition in Viability Assays
2026-08-14
Learn how AZD0156 (SKU B7822) can support better-controlled cell viability, proliferation, and cytotoxicity studies by combining selective ATM pathway inhibition with practical formulation guidance. This scenario-driven guide addresses metabolic assay confounding, solvent compatibility, protocol design, interpretation, and product-selection criteria.
-
Q-VD(OMe)-OPh: Pan-Caspase Inhibition Guide
2026-08-13
Q-VD(OMe)-OPh is a broad-spectrum pan-caspase inhibitor for controlled apoptosis experiments. Its recombinant-caspase activity profile and low reported cytotoxicity make it useful for apoptosis assay design, pathway dissection, and interpretation of complex cell-death models.
-
Cardamomin Protects Against Oxidative Ischemic Injury
2026-08-12
The reference study links cardamomin from Amomum villosum stems and leaves to protection against hydrogen peroxide-induced oxidative damage and permanent cerebral ischemia. Its central contribution is a multi-level mechanism involving MEK/ERK-driven NRF2 activation, suppression of oxeiptosis and parthanatos, and improved tissue viability in a rat stroke model.
-
Q-VD(OMe)-OPh: Designing Better Apoptosis Evidence
2026-08-12
A translational guide to using Q-VD(OMe)-OPh as a mechanistic control in complex cell-death studies, with lessons from cetuximab-resistant colorectal cancer research and applications in cancer differentiation and neuroprotection.
-
WEHI-539: Practical BCL-XL Apoptosis Workflows
2026-08-11
Learn how WEHI-539, SKU A3935, can improve the interpretation and reproducibility of BCL-XL-dependent apoptosis experiments. This scenario-driven guide covers assay design, handling constraints, mechanistic controls, data interpretation, and vendor-selection considerations.
-
Naftifine HCl: A Cross-Scale Assay Framework
2026-08-11
Naftifine HCl is an allylamine antifungal agent whose sterol-targeting mechanism supports rigorous, multi-readout fungal assays. This article applies the evidence architecture of a landmark WNT5a/GSK3/β-catenin study to improve assay design while clearly separating fungal pharmacology from muscle-cell biology.